Cart
sales@molnova.com
Monalizumab
CAS No. 1228763-95-8
Monalizumab( —— )
Catalog No. M36667 CAS No. 1228763-95-8
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 938 | In Stock |
|
| 10MG | 1311 | In Stock |
|
| 25MG | 1881 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMonalizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionMonalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).
-
DescriptionMonalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
-
In Vitro——
-
In VivoAnimal Model:immunodeficient mice xenografted with Cal-27 HLA-E high tumor cellDosage:50?μg, together with 8?millions of activated NK cells Administration:intratumoral injections Result:Shows a synergestic antitumor effect.Enhanced NK-cell killing, and induces lysis of tumor cells.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetChk
-
RecptorChk | IFNAR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1228763-95-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263.?
molnova catalog
related products
-
PV-1019
A potent, ATP-competitive and highly selective Chk2 inhibitor with IC50 of 138 nM.
-
GDC-0425
A potent, selective and orally active Chk1 inhibitor; enhances gemcitabine efficacy in tumor xenograft models.
-
CCT-244747
A novel, potent, highly selective, orally active, ATP competitive CHK1 inhibitor with biochemical IC50 of 8 nM; displays 75-fold selectivity against FLT3 and >1,000-fold selectivity against CHK2 and CDK1.
